Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Rockwell Medical, Inc. Analyst Rating Update - Insider Trading Report |
 |
 |
|
As many as 5 brokerage firms have rated Rockwell Medical Technologies (NASDAQ:RMTI) at 1.8. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 1 analysts have rated it as strong sell. 4 analysts rated the company as a strong buy. Rockwell Medical, Inc. (NASDAQ:RMTI): The mean short term price target for Rockwell Medical, Inc. (NASDAQ:RMTI) has been established at $16 per share. The higher price target estimate is at $26 and the lower price target estimate is expected at $4 according to 5 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $7.97 Rockwell Medical, Inc. (NASDAQ:RMTI) : On Thursday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $12.88 and hit $13.19 on the upside , eventually ending the session at $13.09, with a gain of 1.79% or 0.23 points. The heightened volatility saw the trading volume jump to 555,233 shares. The 52-week high of the share price is $13 and the company has a market cap of $657 million. The 52-week low of the share price is at $8.095 . Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
